Retatrutide Results Timeline
Retatrutide Results Timeline: What the Trials Measured
Published by Peptara Labs · Updated · How we research and check our pages
The short answer
The retatrutide results timeline comes from one 48 week phase 2 trial, not from personal reports. In the highest dose group, mean body weight fell about 17.5% by week 24 and about 24.2% by week 48 (Jastreboff et al., 2023). These are group averages measured under research conditions, not a forecast for any one person.
This page is general educational information, research-use framing only, not medical advice. Research-grade retatrutide is supplied for laboratory research only, not for human use.
What did the retatrutide trial measure over time?
The phase 2 trial tracked mean percentage change in body weight across 48 weeks in adults with obesity, with the largest reductions in the highest dose group (Jastreboff et al., 2023).
This was a randomized, placebo-controlled trial that assigned participants to several dose groups or placebo. The main readout was percentage change in body weight, measured at set checkpoints through week 48. The page below reports those phase 2 results only; results from larger, later trials are not published here.
One point matters for a timeline: these numbers are group means. The trial reported the average change across everyone in a dose group. Individual participants sat above and below that average.
How much weight loss did retatrutide show at 24 weeks?
In the highest dose group, mean body weight fell about 17.5% by week 24 (Jastreboff et al., 2023).
Week 24 is the halfway mark of the 48 week trial. Reaching about 17.5% by the midpoint shows that the early part of the curve is where most of the change accumulated. That early-and-fast pattern is common across incretin-class research and is one reason a results timeline looks like a steep slope that gradually bends.
How much at 48 weeks, the full trial window?
By week 48, the highest dose group reached a mean of about 24.2% below baseline (Jastreboff et al., 2023).
This is the top-line figure most often quoted for retatrutide. All reductions in the active dose groups were larger than the placebo group over the same window.
The figures below are what the published phase 2 trial reported (Jastreboff et al., 2023).
| Trial timepoint | Reported mean body-weight change, highest dose group | Source |
|---|---|---|
| Baseline | 0% (reference) | Jastreboff et al., 2023 |
| Week 24 | about -17.5% | Jastreboff et al., 2023 |
| Week 48 (trial end) | about -24.2% | Jastreboff et al., 2023 |
A detail worth flagging: in the phase 2 trial, mean weight was still trending down at week 48 in the higher dose groups (Jastreboff et al., 2023). That means the 48 week figure may not represent a final plateau, and it should not be read as a ceiling or a target.
Why does the results curve slow down over time?
Weight loss on incretin-class therapy is fastest early and tends to flatten as the body adapts (Wilding et al., 2021, STEP 1; Rosenbaum and Leibel, 2010).
Two things drive the bend in the curve. First, in the STEP 1 semaglutide trial, weight fell from the first check at week 4, reached its lowest point (nadir) near week 60, and the rate of loss slowed well before that, so the curve flattens with time on treatment (Wilding et al., 2021). Second, as a person loses weight, resting energy expenditure falls more than body-size change alone would predict, a response called adaptive thermogenesis (Rosenbaum and Leibel, 2010). This physiology resists further loss and helps explain why early weeks show the biggest moves.
How does the retatrutide timeline compare to tirzepatide and semaglutide?
Retatrutide's 48 week mean is numerically the highest of the three, but each trial ran for a different length, so the timelines are not a fair head-to-head (Jastreboff et al., 2023; Jastreboff et al., 2022; Wilding et al., 2021).
| Compound | Trial | Trial length | Reported top-line mean | Source |
|---|---|---|---|---|
| Retatrutide (highest dose group) | Phase 2 | 48 weeks | up to about -24.2% | Jastreboff et al., 2023 |
| Tirzepatide | SURMOUNT-1 | 72 weeks | up to about -22.5% | Jastreboff et al., 2022 |
| Semaglutide | STEP 1 | 68 weeks | about -15% | Wilding et al., 2021 |
Read the table with care. Retatrutide reached about 24.2% in 48 weeks, while the tirzepatide and semaglutide figures come from longer trials of 72 and 68 weeks. Different enrollment, trial designs, and endpoints also separate these studies. The honest read is that retatrutide's phase 2 numbers look strong on their own timeline, not that one drug "beats" another in a direct comparison.
What happens to results after treatment is withdrawn?
Trials of related incretin therapies report meaningful weight regain after treatment stops (Aronne et al., 2024; Wilding et al., 2022).
When tirzepatide was withdrawn in SURMOUNT-4, participants regained a substantial share of lost weight (Aronne et al., 2024). A similar pattern appeared after semaglutide stopped in the STEP 1 extension (Wilding et al., 2022). The adaptive thermogenesis physiology above is part of why (Rosenbaum and Leibel, 2010). Retatrutide-specific withdrawal data is limited in the published record here, so this pattern is inferred from related GLP-1-class trials rather than measured on retatrutide directly.
Do group means predict individual outcomes?
No. These are averages from a controlled research setting, not a forecast for any individual.
Group means hide wide variation. Within each dose group, some participants lost far more than the average and some far less (Jastreboff et al., 2023).
Keep reading
Related research and verification
Retatrutide Results Timeline: FAQ
What weight-loss numbers did retatrutide reach at 24 and 48 weeks?
In the highest dose group, mean body weight was about 17.5% below baseline at week 24 and about 24.2% below baseline at week 48 (Jastreboff et al., 2023). Both figures are group averages.
Which dose group reached about 24.2%?
The highest dose group in the phase 2 trial (Jastreboff et al., 2023).
Did every participant lose about 24%?
No. That figure is the mean for the highest dose group. Individual results were higher and lower than the average (Jastreboff et al., 2023).
Is retatrutide's timeline better than tirzepatide's?
Retatrutide reached a higher mean at 48 weeks than tirzepatide's SURMOUNT-1 mean of up to about 22.5%, but SURMOUNT-1 ran 72 weeks and the trials differ in design, so this is not a head-to-head result (Jastreboff et al., 2023; Jastreboff et al., 2022).
Will weight loss continue past the numbers shown?
The phase 2 curve had not clearly plateaued at week 48 in the higher dose groups (Jastreboff et al., 2023), but weight loss on incretin therapy generally slows over time (Wilding et al., 2021, STEP 1). Longer outcomes for retatrutide are not reported here.
What happens to weight after treatment is withdrawn?
Trials of related incretin drugs report notable weight regain after withdrawal (Aronne et al., 2024; Wilding et al., 2022). Direct retatrutide withdrawal data is limited in the sources here.
Is this medical advice?
No. This page reports what the trials measured. It is not a recommendation, a dose, or a guarantee.
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
General educational information only, research-use framing, not medical advice. Research material is for laboratory research only, not for human use.